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Abstract. Background: Ectopic secretion of human chorionic
gonadotrophin free beta (hCGβ) by epithelial cancer is
associated with aggressive tumors which more readily
metastasize, possibly by acting as an autocrine anti-apoptotic
agent. hCGβ is encoded by six homologous CGB genes, with
poorly-understood variable transcriptionally active expression
profiles; CGB1 and CGB2 have always been considered
pseudogenes. However, transcripts from CGB1 and -2 can be
detected in placental, testicular and pituitary tissues. The
expression and function of these genes in cancer is less well-
known. Materials and Methods: Expression profiles of CGB
genes in epithelial cancer cells by quantitative polymerase chain
reaction (qPCR) were explored, along with the consequence of
specific siRNA silencing of CGB1 and 2. Immunohistochemical
and immunoassay techniques were used to detect the translation
and secretion of hCGβ in these cells. Results: CGB1 and -2
gene transcripts were only detected in cells which secreted
hCGβ. siRNA-mediated silencing of CGB1 and -2 transcripts
significantly reduced secreted protein in concordance with a
reduction in cell survival to a greater degree than that of other
CGB genes. Conclusion: CGB genes 1 and 2, previously
considered as pseudogenes, are notably expressed by epithelial
cancer cell lines. The transcription of these genes, but not other
CGB genes, correlates with a functionally expressed protein and
propensity for cancer growth. 
Ectopic expression of human chorionic gonadotropin free
beta-subunit (hCGβ) by many types of epithelial cancer is
now a recognised phenomenon, overall, in ~32% of
carcinomas (9-55% in different cancer subtypes) (1, 2).
Such expression is associated with poor prognosis in 87%
of cases where prognosis was investigated (1). However, the
underlying molecular mechanisms of expression and
subsequent influence on oncogenesis are poorly-understood.
We reported that hCGβ acts as an autocrine growth factor
(3) by inhibiting apoptosis (4). Homodimers of hCGβ have
been identified (5) but are not necessarily required for
autocrine activity or receptor binding (6). The target
receptor for free beta subunit of hCG has not yet been
established (7). However, it has been shown that the
hormonal luteinizing hormone (LH)/hCG receptor is not
implicated (8). It has been inferred that hCGβ-positive cells
have a selective survival advantage and potentially undergo
further replication and mutation as a result of CGB gene
expression. 
The beta subunit of hCG is encoded by six CGB genes:
CGB (originally CGB3), CGB5, CGB7 and CGB8 (classical
hCGβ genes), located on chromosome 19q13.3 in close
proximity to CGB1 and CGB2 and the gene for LHβ (CGB4)
(9) (Figure 1). While classical CGB genes have been shown
to be functional, genes CGB1 and CGB2 were always
assumed to be pseudogenes (10). 
Unlike the classical CG genes, which each produce a single
mRNA transcript, CGB1 and CGB2 potentially have four
splice variants (11) (Figure 1). The four variants include a
predominant transcript coding a theoretical 132-amino-acid
protein (which has never been isolated or characterised to
date), and three other splice variants: +47, +166, +176 bp that
contain additional DNA sequences (47 bp, 166 bp and 176 bp
respectively) taken from within intron 1. An alternative
theoretical form of +47 bp variant would result from the re-
shift of the open reading frame (ORF) to that of the classical
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hCGβ-coding transcripts, and would therefore produce an
additional short transcript (essentially another exon, which
has been termed exon 1b) from the middle of intron 1 (12,
13). Alternative mRNAs +166 bp and +176 bp may
hypothetically code for a shorter polypeptide of about 60
amino acids in length (12, 14). Additionally, in testes, a novel
rare splice variant form was detected which contains an extra
87-bp exonic sequence (13).
The incorporation of CGB1 and CGB2 within the human
genome is believed to have evolved in the cluster as a result
of a DNA fragment insertion (736 bp for CGB1 and 724 bp
for CGB2) that replaced the 52-bp sequence at the proximal
end of the promoter, and also the entire 5’-UTR of the
ancestral hCGβ-subunit coding gene fragment, which is still
present in classical CGB genes (11, 15). Replacement of the
CGB5’-UTR provided a novel putative promoter segment, 5-
UTR and exon 1 (which codes for a lead sequence cleaved
during synthesis). A single bp frameshift in the ORF for
exons 2 and 3 in genes CGB1 and -2 has been proposed to
result in an optional earlier stop codon and shorter exon 3 in
the transcripts. Thus, expression of CGB1 and -2 genes may
serve as a template for a hypothetical protein that is entirely
different from the hCG beta subunit of pregnancy, one that
lacks similarity to any known hCG protein (11). Previously
CGB1 and -2 transcript mixtures have been detected in the
placenta (11, 16), testes (17), pituitary gland (18) and other
non-cancerous, non-trophoblastic tissues (12). The mRNAs
of CGB1 and -2 were observed in brain tissue at a level equal
to that found in placenta (19). However, all were detected at
much lower levels than that of classical CGB genes expressed
by placenta.
In cancer, overexpression of CGB genes does not
necessarily correlate with hCGβ protein levels (1). However
when CGB genes are silenced, both the secretion and effect
of hCGβ are negatively impacted (20, 21). More
specifically, the genes CGB, CGB5 and CGB8 are found to
be variably expressed in cancer tissue such as of the breast,
thyroid, and prostate, but not in non-cancerous tissues of
corresponding organs (22), and the genes CGB8, CGB5,
CGB and CGB7 (in order of decreasing expression) were
found unregulated in invasive breast tumors. CGB7 was
also detected in normal breast tissue (23). Additionally,
overexpression of CGB, CGB5 and CGB8 in bladder cancer
cell lines but lower expression of CGB7 was shown by
others (24, 25). In all these studies, neither CGB1 nor
CGB2 were specifically addressed within the experimental
design, in some cases, perhaps, because they have always
been considered pseudogenes and therefore of no
significance (10). 
In the present study, we re-examined CGB gene expression
in non-trophoblastic cancer cells, with a particular focus on
the often disregarded genes CGB1 and -2, to explore their
potential function in cellular oncogenesis. 
Materials and Methods
Cell culture and controls. The human bladder cancer cell lines
RT112, SCaBER and T24, breast cancer cell lines C2235 and
C2238, and prostate cancer LN-CAP and PC-3 were obtained from
the American Type Culture Collection (Manassas, VA, USA) and
from the European Collection of Animal Cell Cultures (Porton
Down, Dorset, UK). Cells were cultured in RPMI-1640 medium
(Invitrogen, Paisley, Scotland, UK) supplemented with 10% fetal
bovine serum (FBS) (Invitrogen) with 5% antibiotics at 37˚C in 5%
CO2. Positive and negative controls were normal-term placental
tissue (placenta obtained after vaginal delivery in the 39th week of
pregnancy) and fresh water shrimp, which has no CG-like genomic
sequence, respectively.
Immunohistochemical staining. Cancer cells were grown, as above,
on cover slips until they reached 80% confluence, and then fixed in
4% paraformaldehyde followed by incubation in 3% H2O2 and
washing in phosphate buffered saline (PBS). For permabilization,
0.1% Triton in PBS was added for 8 min, then cells were washed
three times in PBS, and then blocked in 50% horse serum for 15
min. The cells were incubated for one hour with 1:100 (diluted in
PBS) primary mouse monoclonal anti-hCG beta epitope 7 antibody
(INN-hCG-68; Abcam, Cambridge, Cambridgeshire, UK) followed
by washing in PBS. This method has been described previously (26).
This antibody does not cross-react with intact hCG or hLH/LH free
beta-subunit (17, 27). In the control samples, primary antibodies
were excluded and substituted with PBS. For detection, we applied
the ABC technique and used Vectastain Universal Elite ABC kit
(Vector Laboratories, Peterborough, Cambridgeshire, UK) according
to the protocol described by the manufacturer. Peroxide/3,3'-
Diaminobenzidine (DAB) solution was applied until required stain
intensity develops. The cell nuclei were counterstained with
haematoxylin for 2 minutes. 
Positive control paraffin-embedded sections of term placenta were
de-paraffinised and rehydrated. Antigens were retrieved by heating
in a microwave in citrate buffer (10 mM, pH=6.0) followed by
blocking in horse serum and sequence of incubations as described
above for cancer cells. 
The immunoreactivity score for hCGβ immunohistochemistry was
graded by two researchers independently and then agreed as negative
(–ve), uncertain (+/−); weakly positive (+), strongly positive (++) and
intensely positive (+++), as previously described (26).
RNA extraction and cDNA synthesis. Total RNA was isolated from
all cells using SV Total RNA Isolation System (Promega,
Southampton, Hampshire UK). One microgramme of total mRNA
was used for cDNA first-strand synthesis by Verso cDNA Kit using
oligo-dT primer and random hexamers in a 1:3 ratio (Thermo
Scientific, Loughborough, Leicestershire, UK). 
Quantitative real-time PCR. Relative quantification of CGB gene
expression for the cells was carried out in Quantica thermocycler
(Techne, Stone, Staffordshire, UK) using ABsolute™ Blue QPCR
SYBR® Green Mix kit (Thermo Scientific) with ROX passive
reference dye as recommended by the manufacturer using 2 μl of
cDNA sample. The amplification program consisted of 1 cycle of
95˚C 10 min, followed by 40 cycles of 95˚C for 10 sec, annealing
60˚C for 5 sec, and 72˚C for 9 sec. After termination of 45 cycles, a
dissociation curve analysis was performed. 
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All primers were designed in NCBI/Primer3 – BLAST tool and
purchased from Sigma (Sigma Life Science, Gillingham, Dorset, UK).
One set of primers were specific for CGB1 and -2: forward primer (5’-
CGTCCAACACCCCTCACTCC-3’) designed to anneal to nucleotides
118-137 in mRNAs of human CGB1 and mRNA of human CGB2
(GenBank accession no. NM_033377 and NM_033378, respectively),
and reverse-primer (5’-GGCAGCCCTCCTTCTCCAC-3’) to
nucleotides 329-347 of the mRNAs. This set of primers span intron 1
and consequently all major known spliced variants (Figure 1) would
be detected. The second set of primers (F 5’-CAGCA
CCTTTCTCGGGTCAC-3’ and R 5’- CAGGGAGTAGGGTGTAGG
AAGG-3’) were specific for classical CGB gene mRNAs and designed
to anneal to nucleotides 10-30 and nucleotides 73-95 (GenBank
accession no. NM_033183). In order to check the integrity of the
reverse transcriptase reaction, the expression of the housekeeping gene
encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
amplified using a specific primer set (F 5’-CATGGGTGTGAACC
ATGAGAAG- 3’ and R 5’-GTGCTAAGCA GTTGGTGGTGC-3’)
was used as an endogenous control (GenBank accession no.
NM_002046) in all reactions. Non-emplate control (NTC) contained
complete qPCR master mix, but no cDNA.
Separation and sequencing of PCR products. Real-time PCR products
were detected by Microchip Electrophoresis System MCE-202
MultiNA (Shimadzu, Milton Keynes, Buckinghamshire, UK) according
to manufacturer instructions for DNA-500 kit (Shimadzu). The precise
size estimation length of DNA products was based on separation of 25-
bp DNA ladder (Invitrogen) on MultiNA electrochip system. As
confirmation, qPCR products were also separated on 1% agarose gel,
excised and purified with PureLink™ Quick Gel Extraction Kit
(Invitrogen), and sequenced by GATC Biotech (London, UK). 
Relative quantification of the level of CGB mRNA transcripts. For the
calculation of relative quantity of CGB genes, we applied the ΔΔCp
method described by Livak and Schmittgen (28). The level of
transcription of CGB1 and -2 and classical CGB genes was normalised
against housekeeping gene GAPDH levels and calculated to relative
gene expression in placental tissue (calibrator). Mean crossing point
values (from triplicate reactions) were used in relative quantification.
Final results are expressed as N-fold differences in CGB expression
relative to calibrator gene expression level equal to 1.0.
siRNA silencing of CGB gene expression. The siRNA duplexes (Sigma-
Aldrich, Gillingham, Dorset, UK) were designed primarily to target
mRNA arising from the published sequences for CGB2 (GenBank
accession no. NM_033378) and CGB8 (GenBank accession no.
NM_033183). These duplex sets were distinct in target but CGB2
siRNA duplexes cross-hybridized significantly (100%) with CGB1, and
the CGB8 siRNA duplexes significantly cross-hybridized (>95%) with
all classical CGB genes (Table I). Bladder cancer cell line SCaBER cells
were transfected with siRNA duplexes using CodeBreaker™siRNA
Transfection Reagent (Promega, UK) according to the manufacturer’s
protocol. A total of 5×103 cells per well were plated into 100 μl
complete growth medium in 96-well plates (BD Falcon, Oxford,
Oxfordshire, UK) and allowed to grow for 24 h (until they were 50%
confluent). Cells were then transfected with siRNA at a final
concentration of 15 nM, 20 nM and 25 nM of siRNA in sets of six
replicates. Plates were incubated for a further 72 h at 37˚C and 5% CO2.
A non-specific siRNA targeting enhanced green fluorescent protein
(EGFP) was included as a transfection response control. Negative
controls were cells which had been treated with the transfection reagents
(CodeBreaker™siRNA; Promega), but without any siRNA. 
Determination of secreted hCG and hCGβ protein by cancer cells.
The media from confluent cell cultures grown in 75 cm2 flasks from
before and after specific CGB gene silencing were harvested for
hCGβ protein quantification. hCGβ concentration was estimated
using a two-site FBT-11 immunoenzymetric assay, described
previously (27, 29-32). Cell numbers post-culture, were estimated
using a haemocytometer and used to normalise protein
concentrations (1×106 cells). The assay was calibrated against a
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Figure 1. Diagrammatic representation of the hCGβ gene cluster and comparison of different hCGβ genes. A. hCGβ-LHβ gene cluster; diagrammatic
representation showing relative positions of the CGB genes, LHB and SNARs. Straight arrows show direction of transcription, and open arrowheads
represent SNAR-G genes. Start codons – ATG1 and ATG2 correspond to alternative open reading frame. B: Schematic of CGB1 and -2 genes compared
to CGB, CGB5, CGB7, CGB8 gene structures, illustrating exon and the intron regions of the CGB genes and indicating the potential three main splice
variants reading through into intron 1 (+47 bp, +166 bp, +167 bp). Translated regions are depicted as black boxes; open reading frames are shown as
open boxes. SNAR-Gs are located in the upstream region of exon 1 of genes CGB1 and -2 and are shown as a smaller black box along the gene line.
standard curve of recombinant hCGβ (Sigma) (range of 50 pg/l to
0.5 pg/l) which had been calibrated against the first international
reference preparation of hCGβ (batch 75/551; NIBSC, Potters Bar,
UK). Intact hCG concentrations were quantified using the USA hCG
Reference Service in-house intact hCG ELISA, utilising the antibody
combination of McAb2119 with 4001-POD (33). This was calibrated
against the 3rd International Standard preparation of hCG (batch
75/589; NIBSC). The limit of detection (lowest standard) for the
intact hCG assay was 0.75 pg/l.
Cell proliferation assay following siRNA transfection. For viability
assays, cells were seeded in complete growth medium, as described
above. Growth medium was replaced with 20 μl of CellTiter 96®
AQueous® One Solution Cell Proliferation Assay reagent (Promega)
and cells were incubated at 37˚C for 1-4 h until colour was well-
developed in a humidified atmosphere with 95% air, 5% CO2. 3-
[4,5,dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-
sulfophenyl]-2H-tetrazolium (MTS) is a tetrazolium salt reduction-
type assay method - absorbance at 490 nm was measured on a
Fluostar OPTIMA (BMG Labtech, Aylesbury, Buckinghamshire,
UK), and optical density was measured and expressed as percentage
change relative to control cultures in 96-well plates. Data were
normalised against the optical density achieved for the untreated
controls, and expressed as a percentage change in cell number. Data
were then pooled between plates and expressed as mean and standard
deviation change in normalised cell populations from quintuplicate
experiments. Statistical significance was conducted using Stats
Direct™ (Altrincham, Cheshire, UK) software in ANOVA, or
Friedman’s two-way analysis (data were not normally distributed).
Results 
Detection and sequencing of CGB gene transcripts. The CGB
genes were detected by two separate sets of primers that
differentiated the CGB genes 1/2 and the classical CGB genes
3, 5, 7 and 8. In all cancer cell lines tested (and placenta
control), transcripts for classical CGB genes were detected
(Figure 2A – product 81 bp) and sequences matched those
predicted in the GenBank database.
The transcripts of CGB1 and -2 genes were found only in
cell lines SCaBER, RT112, C2235 and placenta (Figure 2B –
product 231 bp and 396 bp). All CGB1 and -2 products were
sequenced, and aligned with the known CGB 1/2 sequences
in the GenBank database. In regard to CGB 1/2 transcripts,
sequence analysis identified that the products arose largely
from the expression of CGB2 alone (Figure 3).
No product appeared to be derived from genomic DNA, as
no high molecular mass sequences (containing introns) were
observed.
Relative quantification of the level of CGB gene expression.
CGB gene expression in the cancer cell lines was quantified
and compared to the expression level of CGB genes in term
placenta. Classical CGB genes were expressed at the highest
level in the placental tissue and to a much lesser extent by
cancer cell lines; in some cases less than 1% of that seen in
term placenta. The exceptions were by the bladder cancer cell
line T24 at 1.6%, SCaBER at 3.1%, and by the two breast
cancer cell lines C2335 at 6.3% and C2238 at 25.0% of that
seen in the placental control tissue (Table II).
CGB1 and -2 mRNA was detected in two out of three
bladder cancer cell lines (SCaBER and RT112), where the
expression level was significantly higher in comparison to
term placenta, both 128-fold higher. The breast cancer cell line
C2335 demonstrated a 32-fold higher expression of CGB1/2
mRNA compared to the placental control sample (Table II). 
Detection of hCGβ protein. Immunostaining for hCGβ scored
positively in most of the tested non-trophoblastic cancer cell
lines, albeit at different levels. Significantly, bladder cancer cell
line SCaBER and breast cancer cell line C2235 exhibited very
weakly-positive cellular staining. The remaining cell lines
stained more positively, as did the placental positive control
(Table II). However, the presence and quantity of free hCGβ
protein secreted into the culture media (as measured by specific
hCGβ ELISA) was significant in only three of the cancer cell
lines: The highest level of hCGβ protein in media was seen in
the bladder cancer cell line SCaBER (4.4 ng/106 cells/24 h),
breast cancer cell line C2235 (2.3 ng/106 cells/24 h) and
bladder cancer cell line RT112 (0.78 ng/106 cells/24 h). In the
remaining cancer cell lines (T24, PC-3, LN-CAP, C2238), no
hCGβ was detected in the media (<0.5 ng/106 cells/24 h). No
intact (αβ heterodimer) hCG of pregnancy was detected in any
culture medium (Table II).
Effect of siRNA duplex silencing. Following siRNA control
transfection, secreted hCGβ protein levels ranged from 
3-4.6 pg/l for bladder cancer cells. siRNA CGB2 oligo- duplex
(25 nM) reduced secretion by 96%, while CGB8 oligo-duplex
reduced secretion by 42% of controls. At all concentrations, we
observed that siRNA duplexes effectively inhibited CGB
expression (Figure 4A). We further examined whether viability
of cells in culture could be changed after silencing to determine
the impact of hCGβ secretion on survival. At all concentrations of
siRNA, CGB2 oligo-duplex reduced cell numbers significantly:
25 nM by 44% (p<0.0001), 20 nM by 24% (p=0.0011), and 15
nM by 19% (p=0.02) compared to controls (Figure 4B). In
contrast, the control siRNA directed against the sequence of an
unrelated protein (EGFP) failed to produce any significant
reduction in relative cell numbers, with reduction of only 13%
(p=0.22). When CGB8 gene was targeted by siRNA oligo-
duplex, only the highest concentration (25 nM) resulted in a
significant reduction of cell growth by 23% compared to control
(p=0.0004) (Figure 4B). Non-specific silencing of control EGFP
sequence had no effect on cell numbers (1.01%, p=0.42).
Discussion
The overexpression and secretion of ectopic hCGβ by epithelial
cancer cells is well-reviewed (1, 34-37) such that vaccines
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against hCGβ have been developed and discussed as adjuvant
treatments in cancer (1, 38-40). However, despite the wealth of
evidence in the field, the molecular mechanisms are not well-
defined and occasionally result in discordant data. Previous
studies have failed to correlate CGB mRNA expression with
protein expression as detected by immunohistochemistry and
immunoassays (8). 
Several molecular studies have been conducted on placental
tissues, choriocarcinoma and epithelial cancer (particularly
bladder) to try and establish a model for CGB gene expression.
These are not necessarily comparable as the placenta expresses
both α and β subunits to form and secrete the pregnancy
hormone intact hCG; choriocarcinomas appear to secrete intact
hCG and excess free subunits, and epithelial carcinomas
express and variably secrete only the free β-subunit hCG. 
Due to the high level of homology between the CGB gene
cluster sequences, it is difficult to identify base pair sequences
that are sufficiently specific enough to differentiate individual
CGB genes. In all earlier studies, specific CGB1 and -2 gene
expression was excluded from primer design in the belief that
these were non-functioning genes (pseudogenes) simply
because no functional hCG product has been identified at the
time (10). In placental and choriocarcinoma tissue, all CGB
gene expression was based solely upon mRNA detection (11)
and cancer studies have shown that CGB mRNA is detectable
in both normal and carcinoma tissue. Attempts to differentiate
CGB expression revealed that only CGB7 (then termed CGB
type I) was transcriptionally active in both tumor and normal
tissue and the remaining classical genes (termed type II) were
indicative of cancer (22, 24, 41). In our study, it was not
assumed that CGB1 and -2 genes were transcriptionally silent
and we designed specific primers for CGB1 and -2
amplification which spanned intron 1 to allow detection and
identification of theoretical spliced variants (11, 16-18). 
Critically, our study clearly shows the expression of CGB1
and -2 genes by non-trophoblastic cancer cell lines and at
mRNA levels vastly greater than those seen in the placental
control tissue. Furthermore, sequencing reveals that this is
largely due to the expression of CGB2 rather than that of
CGB1. CGB1 and CGB2 only vary by two nucleotides at
positions 185 and 223 (accession numbers NM_033377.1 and
NM_033378.1, respectively). The predominant nucleotides
detected at these sequence positions were C and G, indicative
of CGB2 (Figure 3). 
The molecular basis of earlier studies to distinguish between
CGB gene expression was that type I gene (CGB7) encodes an
alanine at position 117, whilst type II encode an aspartic acid
(24), and it is this which is associated with malignant
transformation of epithelial cells. At first, this appears to be
inconsistent with our findings, but it is entirely plausible that
the technology employed previously (22, 41) was incomplete.
Indeed, the competitive oligonucleotide priming (COP) assay
employed (which relies on differential binding on a single base
pair mismatch) would have hybridised with CGB1 and -2
mRNA. Examining GenBank CGB gene sequences (Table III),
it was found that mRNA arising from CGB1 has the GAC
codon (ASP) and CGB2 gene has GCC codon (ALA) at amino
acid position 117. Thus, of mRNA discarded, that arising from
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Table I. Detail of siRNA sequences used for silencing CGB genes. siRNA sequences used for silencing CGB2 (and 1) and CGB8 (and CGB, CGB5,
-7 and -8); their location on mRNA mapping to base-pairs on exon 1 (according to GenBank accession number NM_033378 for CGB2 and
NM_033183 for CGB8, respectively) and the degree of homology between the siRNA duplexes and the different CGB gene sequences.
Target gene
Nucleotide siRNA duplex Sequence Between-gene homology (%)
position in exon 1
CGB1 CGB2 CGB3 CGB5 CGB7 CGB8
CGB 2 Sense 1: CAGUGCUUGCGGAAGAUAU dTdT 100 100 37 37 37 42
position: 188 Antisense 1: AUAUCUUCCGCAAGCACUG dTdT
CGB 2 Sense 2: CACGGAGACUCAAUUUACU dTdT 100 100 42 37 37 37
position: 152 Antisense 2: AGUAAAUUGAGUCUCCGUG dTdT
CGB 2 Sense 3: CGCUAAGAGAGAGACAUGU dTdT 100 100 42 42 42 42
position: 209 Antisense 3: ACAUGUCUCUCUCUUAGCG dTdT
CGB 8 Sense 1: UCACUCCAGCAUCCUACAA dTdT 28 28 84 95 100 100
position: 280 Antisense 1: UUGUAGGAUGCUGGAGUGA dTdT
CGB 8 Sense 2: AGGUUUAAAGCCAGGUACA dTdT 42 42 95 95 95 100
position: 322 Antisense 2: UGUACCUGGCUUUAAACCU dTdT
CGB 8 Sense 3: AGUCUCUGAGGUCACUUCA dTdT 0 0 100 95 95 100
position: 135 Antisense 3: UGAAGUGACCUCAGAGACU dTdT
EGFP Sense 1: GCAAGCUGACCCUGAAGUUCAU dTdT 0 0 0 0 0 0
Antisense 1: GAACUUCAGGGUCAGCUUGCCG dTdT
CGB1 would have registered as type I and that arising from
CGB2 as type II. Here we found that abundant mRNA from
CGB2 correlated with expressed and secreted free hCGβ
protein and confounds the COP assay. 
A more recent study, using similar real-time PCR to our
study, claimed they were unable to detect any increase in gene
CGB1 and -2 expression (23); it should be noted that they
exclusively studied normal breast and breast tumour samples.
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Figure 2. Electrophoresis and elecropherogram of qPCR products on Microchip Electrophoresis System MultiNA. Separation of real-time PCR products
and analysis by electrophoresis system MultiNA. A: Amplification of classical CGB genes by quantitative PCR. The desired product is seen in appropriate
lanes: placenta, SCaBER, RT112, T24, C2235 and C2238. B: PCR products obtained during amplification of genes CGB1 and -2. The product 231 bp
corresponds to calculated specific product of CGB1 and -2, whilst the primers are the bands below 25 bp. In addition +166 bp splicing variant was
amplified (with calculated by MultiNa software mass 396 bp). The position of upper (UM) and lower (LM) marker dyes of the MultiNA separation are
indicated, as is the position of the base pair reference mass markers. The ladder (Invitrogen) shows the bands between 25 bp and 450 bp. Any slight
difference in size of product is caused by variations in separation on different microchips. Non-template control (NTC) and negative control (Neg ctrl)
are indicated. Representative electropherograms from MultiNA electrochip system of separated PCR products amplified (A) with CGB, CGB5,-7 and -
8 primers with a mass of 81 bp (B) and with CGB1 and -2-specific primers with predominant product with a mass of 231 bp (calculated 229 bp), and
less abundant 396 bp. LM and UM were used for calibration according to the manufacturer. The axes of the plot indicate migration index (x) and
fluorescence intensity (y). Each peak in the electropherogram represents a DNA fragment of PCR product or primer which migrates according to
molecular weight. Migration index is inversely proportional to the length of DNA fragments and is used by software to calculate exact mass. 
Figure 3. Sequencing analysis of CGB1 and -2 qPCR products. Sections of specific sequencing of CGB1 and -2 PCR products (both 231 bp and 396 bp)
were sequenced indicating the single marker nucleotide differences between CGB1 and CGB2 mRNA (at nucleotides 185 and 223 - accession numbers
NM_033377.1 and NM_033378.1 respectively). This demonstrates that expression of CGB2 mRNA is the predominant source of CGB1/2 RT-PCR product
detected in qPCR with CGB1/2-specific primers.
In this study, we also found contradictory patterns of CGB gene
expression in the breast cancer cell lines: C2238 did not secrete
hCGβ into culture media and did not express CGB1 and -2
genes, but did stain strongly for hCGβ on immunohisto-
chemistry and expressed relatively high levels (25% of that of
third trimester pregnancy) of classical CGB genes. C2235
secreted high levels of hCGβ into culture media, expressed high
levels of CGB1 and -2 genes, but stained weakly for hCGβ on
immunohistochemistry and expressed relatively low levels (6%
of that of third trimester pregnancy) of classical CGB genes.
Most significantly, in this study, such CGB2 gene expression
was only found where hCGβ protein was detected as a secreted
(culture media) product. However, the multiple splice variants
arising from CGB1 and -2 genes had been presumed by others
to translate into a non hCGβ-like protein. This proposed protein
was purported to initiate translation from an alternative ATG
start site (ATG1) located 47 nucleotides upstream from the
conserved classical CGB mRNA start site (Figure 1).
Interestingly ATG1 is not present in the other CGB genes due
to splicing. Moreover, putative 155- and 163-amino-acid
proteins (translated from an ATG2 ORF within genes CGB1
and -2 respectively) are of a comparative size to ‘classical’
CGB gene transcripts and share up to 98% sequence homology.
In the present study of CGB1 and -2 gene expression by
epithelial cancer, we found that the predominant mRNA spliced
variant arising from CGB2 is a fully-spliced 231-bp product
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Table II. Relative quantification of CGB gene expression by cancer cell lines and placental tissue compared with detection of hCGβ by
immunohistochemistry, and  hCGβ and intact hCG secretion into culture media by specific ELISA. Average crossing points (Cp) were normalised
to the GAPDH level in order to correct for variation in total cDNA concentration between samples. Normalised expression was compared as relative
to that detected in the placental tissue extract which was adopted as an internal calibrator. ND: Not detected, gene expression level was, therefore,
not quantified. The immunoreactivity score was graded using a semi-quantitative scoring system which scored both the percentage of positively
stained cells and the intensity of immunopositivity as negative (–ve), uncertain (+/−), weakly positive (+), strongly positive (++) and intensely
positive (+++). Scoring was based on positivity seen in control placental tissue.  The level of hCGβ protein secreted into the culture media by the
tumor cell lines (106 cells cultured for 24 h) was determined by specific immunoassay for free hCGβ and intact hCG. 
Cell line or Normalised Cp Level relative  Immunostaining Secretion of hCGβ Secretion of hCG 
tissue to placenta for hCGβ (ng/1×106 cells/24 h) (ng/1×106 cells/24 h)
CGB(3),5,7,8 CGB1/CGB2 CGB(3),5,7,8 CGB1,2
Placenta 22 34 1 1 + + + - -
SCaBER 27 27 0.0313 128 + 4.4 <0.5
RT112 30 27 0.0039 128 + + 0.78 <0.5
T24 28 ND 0.0156 ND + + + <0.5 <0.5
PC-3 31 ND 0.002 ND + + + <0.5 <0.5
LN-CAP 30 ND 0.0039 ND + + <0.5 <0.5
C2235 26 29 0.0625 32 + 2.3 <0.5
C2238 24 ND 0.25 ND + ++ <0.5 <0.5
Table III. Alignment of CGB gene mRNA corresponding to exon 3 coding for amino acid 117. Sequence alignment shows that the triplet codon variant
GCC (alanine) previously considered unique to hCGβ protein arising from transcription of CGB7 is also found in CGB2. The location of the mutation
corresponds to amino acid position 117 usually aspartic acid (GAC). The mRNA GenBank accession number and base pairs position of sequences are
indicated in Bold.
Accession number Gene Sequence
NM_033043 CGB5 TGACTGCGGGGGTCCCAAGGACCACCCCTTGACCTGTGATGACCCCCGCTTCCAGGACTC  
bp726-785
NM_033183 CGB8 TGACTGCGGGGGTCCCAAGGACCACCCCTTGACCTGTGATGACCCCCGCTTCCAGGACTC  
bp726-785
NM_000737 CGB TGACTGCGGGGGTCCCAAGGACCACCCCTTGACCTGTGATGACCCCCGCTTCCAGGACTC  
bp726-785
NM_033142 CGB7 TGACTGCGGGGGTCCCAAGGACCACCCCTTGACCTGTGATGACCCCCGCTTCCAGGCCTC  
bp726-785
NM_033378 CGB2 TGACTGCGGGGGTCCCAAGGACCACCCCTTGACCTGTGATGACCCCCGCTTCCAGGCCTC  
bp-571-630
NM_033377 CGB1 TGACTGCGGGGGTCCCAAGGACCACCCCTTGACCTGTGATGACCCCCGCTTCCAGGACTC 
bp-571-630
(shown in the electropherogram, Figure 2B), which sequenced
as predicted, and would therefore have been available for
translation to a mature hCGβ-like protein. 
It has been proposed that the expression of CGB type II
genes significantly increases in many non-trophoblastic
malignant tissues and may correlate with elevated levels of
hCGβ in patients’ serum. The results obtained by our study
showed expression of all classical CGB genes by all non-
trophoblastic cell lines. However, this does not correlate
with secreted protein levels. Immunohistochemical
detection indicates that protein expressed might be held
intracellularly for the majority of cancer cell lines, and not
secreted. A possible explanation may be that transcription
and translation of the CGB gene cluster does not result in
secretion per se, and that more specific gene or cellular
processing may be required for active autocrine/paracrine
expression. The levels of mRNA arising from classical
CGB genes in our cell lines are generally less that 1% of
that found in third trimester placental tissue. Interestingly,
in one breast cancer cell line (C2238), mRNA levels were
as high as 25% of that seen in placental tissue, yet no
secreted hCGβ protein was detected. 
As already stated, transcriptional messages were detected in
all cell lines using primers designed to amplify classical CGB
genes, including the non-hCGβ protein-secreting bladder
cancer cell line T24. However, mRNA arising from CGB1 and
-2 gene was only detected in placental tissue, breast cancer cell
line C2235, and bladder cancer cell lines RT112 and SCaBER
(Figure 2B). Furthermore, these are the only cell lines studied
which secrete hCGβ protein into their culture media (Table II).
The high level of CGB1 and -2 gene expression in these cancer
cell lines may be evidence of their functionality, and this is
supported by the interesting correlation with protein secretion.
This complex condition of expression may explain ectopic
hCGβ secretion by tumors when simple ‘all CGB’ mRNA
detection in a tumor fails to correlate with circulating levels
found in patients’ blood and urine, as reviewed by Butler and
Iles (1), and explain why molecular and immunological hCGβ
studies often differ. In much the same way as antibody
selection has become important in immunoassays detecting the
right ‘kind’ of hCG for the management of trophoblastic
diseases (42), we might find ourselves having to use the right
kind of molecular markers to improve the diagnostic and
prognostic power of hCGβ in epithelial cancer.
More recently it has been shown that CGB1 and -2 is
expressed in the placenta (14), testes (13, 43) and in ovarian
tissue (44). Moreover, in testis, the predominant CGB1 and -2
mRNA transcript is also a fully-spliced mRNA with translation
initiation from AUG2. This was also proposed to give rise to
an hCGβ protein homologous to the protein coded by classical
CGB genes. Similarly, we have now demonstrated that the
major transcribed splice variant of CGB2 mRNA is fully-
spliced and would result in a recognisable hCGβ peptide in
agreement with these findings (13, 43). A +166 splice variant
was also detected arising from CGB2 gene expression, but at
lower levels in the hCGβ-secreting cancer cell lines. It has been
suggested that these are CGB2a and CGB2b proteins (13, 43)
and that the splice variant +166 bp encodes a novel peptide
using a different open reading frame starting from ATG1.
However, the function of this peptide remains unclear.
To study the possible effect of any hCGβ protein derived
from expression of CGB1 and -2, we inhibited its
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Figure 4. Effect of silencing of CGB1 and -2 and classical CGB genes on bladder cancer cell line SCaBER. A: Secretion of hCGβ into culture media
of SCaBER cancer cells treated with increasing concentrations of siRNA targeting CGB1 (     n     ) and -2 or CGB, CGB5, -7 and -8 (     l ).
Values are expressed as percentage of untreated control and each point is the mean of six replicates of the assay ran in duplicate; the bars represent
standard deviation about the mean. EGFP silencing represents non-specific effects of introducing a non-functioning siRNA.B: Influence of RNA
silencing on SCaBER cell viability – increasing concentration of siRNA (nmol/l) and relative level of viable cells are shown. MTS assay values are
expressed as a percentage that of untreated control. Results are the mean from six replicates of the assay. The bars represent standard deviation about
the means. EGFP silencing represents non-specific effects of introducing a non- functioning siRNA. 
translation by specifically targeting the mRNA with a mix
of siRNA duplexes for different regions within exon 1 of
CGB1 and -2, and CGB8 (with high homology to other
classical CGB genes – Table I). Silencing of CGB genes
with siRNA duplexes resulted in the reduction of the viable
cancer cell number (Figure 3B). However, at all
concentrations of siRNA, CGB2 oligo-duplex cell numbers
were reduced significantly more than if siRNA targeted
classical CGB mRNA. This was also reflected in the
amount of hCGβ protein secreted by the exposed cells, with
CGB2 oligo-duplex siRNA effectively abolishing secretion
(Figure 3A).
Non-specific silencing of CGB gene expression was
shown to induce increased apoptosis of HeLa cells (20) and
inhibit growth of SCaBER cells in vitro (21). The significant
reduction of gene expression was demonstrated using a
modified U1 snRNA in which the first 10 nucleotides were
substituted with a complementary CGB gene sequence
present in exon 3 (20). However, in neither of these studies
was any distinction made between which of the six CGB
genes were silenced. Moreover, silencing of any gene coding
beta subunit of human chorionic gonadotropin could lead to
reduction not only of free hCGβ, but also of heterodimeric
hCG known to be produced by HeLa cells (45-47). Here by
distinguishing the target region more specifically’ we were
able to examine the respective influence of gene groups on
cancer cell viability. 
Specific targeting of CGB1 and -2 is much more effective
in reducing cancer cell numbers than silencing classical CGB
genes, or general silencing of ‘all’ CGB, and although it was
once considered to be a pseudogene, CGB2 may now be
considered an active gene which is important for cancer
growth. Furthermore, CGB2 may interact at the mRNA level
with other gene transcripts such as the snRNA, SNAR-G2
which is encoded adjacent to CGB2 (13, 43, 48) (Figure 1).
The profile of CGB1 and -2 gene expression during the first
trimester correlates with successful pregnancies (14, 16) and
particularly elevated levels of CGB1/2 mRNA were reported
in ectopic and molar pregnancies (12). It can be postulated
that these pregnancy implantation associations, together with
data present here, indicate a role for CGB1 and -2 (possibly
only CGB2)-derived free hCGβ in the invasive process
(elevated free hCGβ is pronounced in early pregnancy). 
In conclusion, up-regulation of CGB2 gene expression in
common epithelial cancer cells suggests an important
function for this presumed pseudogene in ectopic hCGβ
secretion and oncogenesis. This finding could play a
significant role in cancer diagnostics by differentiating
aggressive from non-aggressive tumors.
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